Cingulate (CING) announced the appointment of Bryan Downey as Chief Commercial Officer, CCO, following the U.S. Food and Drug Administration’s, FDA, acceptance of Cingulate’s New Drug Application, NDA, for CTx-1301 and assignment of a Prescription Drug User Fee Act, PDUFA, target action date of May 31, 2026. Cingulate also announced it has completed a $6 million financing transaction, further strengthening its balance sheet and extending its cash runway into the second quarter of 2026, as the company prepares for commercialization, subject to FDA approval.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate presents Phase 3 results for CTx-1301, met primary endpoint
- Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success
- Cingulate price target raised to $17 from $10 at Roth Capital
- Cingulate Inc’s NDA for CTx-1301 Accepted by FDA
- Cingulate announces FDA accepted for review the NDA for CTx-1301